<p>Intratumoral heterogeneity (ITH), arising from various factors, plays a crucial role in diverse cancers, yet research on ITH remains in its early stages. To explore this phenomenon further, we conducted single-nuclei transcriptome profiling on patient-derived organoids (PDOs) from two histologically pure subtypes of gastric cancer. We identified differences in cancer stem cell marker expression among intestinal-type samples and their correlation with one-carbon (1C) metabolism. Notably, some gastric cancer samples, although histologically classified as intestinal-type, exhibited diffuse-like genetic characteristics. This finding suggests the potential for employing a 1C metabolism inhibition strategy as a therapeutic approach for these genetically diffuse-like gastric cancers. This study highlights the necessity of addressing ITH in PDO-based preclinical models and contributes valuable insights toward advancing precision medicine treatments for gastric cancer.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

One-carbon metabolic pathway is a novel molecular signature for CD44-positive intestinal-type gastric cancer

  • Seyeon Joo,
  • Yoojin Bae,
  • Bo Kyung Yoon,
  • Yeonjin Je,
  • Yuna Kim,
  • Minki Kim,
  • Su-Jin Shin,
  • Sungsoon Fang,
  • Jie-Hyun Kim

摘要

Intratumoral heterogeneity (ITH), arising from various factors, plays a crucial role in diverse cancers, yet research on ITH remains in its early stages. To explore this phenomenon further, we conducted single-nuclei transcriptome profiling on patient-derived organoids (PDOs) from two histologically pure subtypes of gastric cancer. We identified differences in cancer stem cell marker expression among intestinal-type samples and their correlation with one-carbon (1C) metabolism. Notably, some gastric cancer samples, although histologically classified as intestinal-type, exhibited diffuse-like genetic characteristics. This finding suggests the potential for employing a 1C metabolism inhibition strategy as a therapeutic approach for these genetically diffuse-like gastric cancers. This study highlights the necessity of addressing ITH in PDO-based preclinical models and contributes valuable insights toward advancing precision medicine treatments for gastric cancer.